Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
1149
mi
from
Baltimore, MD
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Cleveland Clinic Foundation
898
mi
from
Cleveland, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Cleveland Clinic Foundation
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Case Western Reserve Univ
899
mi
from
Cleveland, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Case Western Reserve Univ
899
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Froedtert and the Medical College of Wisconsin
630
mi
from
Milwaukee, WI
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Froedtert and the Medical College of Wisconsin
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Iowa - Holden Comprehensive Cancer Center
429
mi
from
Iowa City, IA
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Iowa - Holden Comprehensive Cancer Center
429
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Ohio State University Comprehensive Cancer Center
810
mi
from
Columbus, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Ohio State University Comprehensive Cancer Center
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Hillcrest Hospital Cancer Center
907
mi
from
Mayfield Heights, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Hillcrest Hospital Cancer Center
907
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Women and Infants Hospital
1424
mi
from
Providence, RI
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Women and Infants Hospital
1424
mi
from
Providence, RI
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Augusta University Medical Center
935
mi
from
Augusta, GA
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Augusta University Medical Center
935
mi
from
Augusta, GA
Click here to add this to my saved trials
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  8/8/2017
Gynecologic Oncology Group
1225
mi
from
Philadelphia, PA
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 8/8/2017
Gynecologic Oncology Group
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Rush University Medical Center
608
mi
from
Chicago, IL
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Rush University Medical Center
608
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Borgess Medical Center
719
mi
from
Kalamazoo, MI
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Borgess Medical Center
719
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Bronson Methodist Hospital
718
mi
from
Kalamazoo, MI
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Bronson Methodist Hospital
718
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
West Michigan Cancer Center
718
mi
from
Kalamazoo, MI
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
West Michigan Cancer Center
718
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Cleveland Clinic Cancer Center at Fairview Hospital
889
mi
from
Cleveland, OH
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Cleveland Clinic Cancer Center at Fairview Hospital
889
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
South Carolina Oncology Associates, PA
968
mi
from
Columbia, SC
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
South Carolina Oncology Associates, PA
968
mi
from
Columbia, SC
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Virginia Cancer Center
1051
mi
from
Charlottesville, VA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Virginia Cancer Center
1051
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Western Regional CCOP
851
mi
from
Phoenix, AZ
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Western Regional CCOP
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Scottsdale Healthcare
835
mi
from
Scottsdale, AZ
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Scottsdale Healthcare
835
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Long Beach Memorial Medical Center-Todd Cancer Institute
1172
mi
from
Long Beach, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Long Beach Memorial Medical Center-Todd Cancer Institute
1172
mi
from
Long Beach, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
UCLA Jonsson Comprehensive Cancer Center
1177
mi
from
Los Angeles, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
UCLA Jonsson Comprehensive Cancer Center
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Community Hospital of Los Gatos
1320
mi
from
Los Gatos, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Community Hospital of Los Gatos
1320
mi
from
Los Gatos, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Palo Alto Medical Foundation-Gynecologic Oncology
1325
mi
from
Mountain View, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Palo Alto Medical Foundation-Gynecologic Oncology
1325
mi
from
Mountain View, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
1154
mi
from
Orange, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
1154
mi
from
Orange, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
UCSF Medical Center at Mount Zion
1340
mi
from
San Francisco, CA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
UCSF Medical Center at Mount Zion
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
North Colorado Medical Center
411
mi
from
Greeley, CO
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
North Colorado Medical Center
411
mi
from
Greeley, CO
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
McKee Medical Center
433
mi
from
Loveland, CO
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
McKee Medical Center
433
mi
from
Loveland, CO
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
The Hartford Hospital
1358
mi
from
Hartford, CT
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
The Hartford Hospital
1358
mi
from
Hartford, CT
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
The Hospital of Central Connecticut
1353
mi
from
New Britain, CT
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
The Hospital of Central Connecticut
1353
mi
from
New Britain, CT
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Beebe Medical Center
1229
mi
from
Lewes, DE
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Beebe Medical Center
1229
mi
from
Lewes, DE
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Christiana Care Health System - Christiana Hospital
1193
mi
from
Newark, DE
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Christiana Care Health System - Christiana Hospital
1193
mi
from
Newark, DE
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Memorial University Medical Center
1023
mi
from
Savannah, GA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Memorial University Medical Center
1023
mi
from
Savannah, GA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Rush - Copley Medical Center
575
mi
from
Aurora, IL
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Rush - Copley Medical Center
575
mi
from
Aurora, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
594
mi
from
Hinsdale, IL
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
594
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Joliet Oncology-Hematology Associates Limited
579
mi
from
Joliet, IL
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Joliet Oncology-Hematology Associates Limited
579
mi
from
Joliet, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Indiana University Melvin and Bren Simon Cancer Center
643
mi
from
Indianapolis, IN
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Indiana University Melvin and Bren Simon Cancer Center
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Saint Vincent Hospital and Health Care Center
642
mi
from
Indianapolis, IN
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Saint Vincent Hospital and Health Care Center
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Franciscan Saint Anthony Health-Michigan City
641
mi
from
Michigan City, IN
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Franciscan Saint Anthony Health-Michigan City
641
mi
from
Michigan City, IN
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Iowa - Holden Comprehensive Cancer Center
429
mi
from
Iowa City, IA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Iowa - Holden Comprehensive Cancer Center
429
mi
from
Iowa City, IA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Norton Hospital Pavilion and Medical Campus
657
mi
from
Louisville, KY
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Norton Hospital Pavilion and Medical Campus
657
mi
from
Louisville, KY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Mary Bird Perkins Cancer Center
637
mi
from
Baton Rouge, LA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Mary Bird Perkins Cancer Center
637
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Medical Center of Baton Rouge
637
mi
from
Baton Rouge, LA
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Medical Center of Baton Rouge
637
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
University of Mississippi Medical Center
571
mi
from
Jackson, MS
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
University of Mississippi Medical Center
571
mi
from
Jackson, MS
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated:  8/23/2017
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Status: Enrolling
Updated: 8/23/2017
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials